Moderna dosed its first group of patients in the second phase of the clinical trial for its vaccine against the coronavirus. The company led the corporate pack in the race to find a viable pandemic vaccine so that people can return to work and return to more normal lives. Therefore, stock prices Moderna surged last month after the company announced the first promising results from the first stage of human trials. However, it now appears that Moderna overestimated the results of the test in favor of the company’s bottom line. Moderna sold 17.6 million shares within hours of its announcement. For what it’s worth, the first test ride only indicates the safety of the test, not the effectiveness. The second series of tests, which compares the vaccine to a placebo, provides a better overall picture of the viability of the vaccine.
In the days following the announcement of the first trials, the company made massive sales of $ 1.3 billion to the public. At the same time, two Moderna executives – chief medical officer Tal Zaks and technical director Lawrence Kim – sold nearly $ 30 million in their combined shares. Both of these sales were executed through automated trading programs for the individuals and businesses involved in the business, which is protection against accusations of using privileged knowledge for profit. However, the timing of Zaks and Kim’s stock sales is suspect. Experts and analysts believe that this is a form of market manipulation, that is, increasing the stock so that it can then be sold.
Only eight people participated in the first cycle of the clinical trial for the coronavirus vaccine. These eight people had levels of neutralizing antibodies in the blood – immune cells that may be able to block the coronavirus – which were comparable to those seen in people who had recovered from the coronavirus. However, it is important to point out at what stage of the Moderna process this trial is. Only about a third of the drugs entering the clinical trial phase reach the final stage. That’s why we don’t hear much about early-stage testing of new drugs and vaccines.
In addition, a vaccine expert said that the level of antibodies found in the plasma of recovered patients may not be enough to neutralize the virus. Basically, this means that the highly anticipated results of Moderna were not necessarily good news. There are also a number of surveys of Moderna’s business practices.
Moderna is advancing in the second stage of the trial with 600 healthy adults divided into two age groups: 18 to 55 years old and people over 55 years old. Moderna announced last week that the first patients in both age groups had been vaccinated with each dose. Each person participating in the trial will receive two doses, with a high dose, a low dose or a placebo. They will be monitored during the year for potential side effects and signs of a neutralizing antibody to the coronavirus. The third stage trial is scheduled to start in July. Members of the National Institute of Allergies and Infectious Diseases estimate that a vaccine may be available on a limited basis by January. We will not know if the results of the phase one trial have really been improved or not until the final vaccine is ready.